Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 84 |
| Active Pipeline (Recruiting Now) | 47 (26) |
| Completed vs Stopped Early | 16 / 20 (23.8%) |
| Median Closed Actual Enrollment | 40 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Northwestern Memorial and Lurie Cancer Center | Chicago, IL | 72 |
| University of Chicago Medicine | Chicago, IL | 8 |
| Northwestern Medicine Orland Park | Orland Park, IL | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07293650 | PREcision MEDicine In Achalasia (PREMEDIA) | Phase III | RECRUITING |
| NCT04576104 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Northwestern University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.